Fractional
CFO Leadership
for Life Sciences
For biotech and life sciences teams that need a finance executive who can lead the board conversation and personally run the forecast, manage runway, drive reporting discipline, and support financings without requiring a full finance team behind them.
First 30-minute consultation at no cost.
Yasser Hazzaa founded YH CFO Consulting on more than 25 years of life sciences finance leadership at Bristol Myers Squibb and MannKind Corporation. He works with biotech and growth-stage companies to strengthen planning, improve liquidity discipline, and deliver board-ready reporting.
His experience includes strategic planning for a $17 billion business, contributing to 600% market cap growth at a public company, and serving on private company boards with audit and finance oversight.
Yasser brings both board-level perspective and hands-on execution. In lean environments, he does not stop at recommendations. He builds the forecast, drives reporting discipline, prepares financing and board materials, and works directly with operating leaders to close the gaps and move the business forward.
Trusted Experience Across
Leadership at a Glance
Executive Impact
25+
Years of Finance Leadership
Bristol Myers Squibb & MannKind Corporation
3
Regions of Finance Leadership
North America, Europe, and MENA
150+
Global FP&A Community
Built and led at Bristol Myers Squibb
2
Board Governance Experience
TesoRx Pharma and Lipac Oncology
Finance leadership tailored to where you are today
Strategic and hands-on finance leadership for life sciences companies, structured around the stage and complexity of your business.
Pre-Revenue
- Board-ready finance leadership and materials
- Capital strategy and allocation support
- Cash forecasting with early warning indicators
- Runway protection and cost action planning
Commercial
- FP&A, budgeting, and long-range planning
- KPI dashboards with owners and targets
- Board reporting pack and decision materials
- Rolling forecast and operating cadence
Scaling
- Due diligence and integration planning
- Performance transformation and margin protection
- Unit economics reset and accountability cadence
- Vendor rationalization and contract economics
What I personally take on
I step in quickly and take direct ownership of the finance work that keeps decisions moving when the team is lean or leadership coverage is thin.
- Lead the board and audit committee cycle with clear, decision ready materials that I prepare and present.
- Own capital strategy including runway modeling, financing scenarios, and the investor narrative.
- Drive the FP&A engine through rolling forecasts, budgets, and long range planning.
- Build reporting infrastructure that sharpens execution through dashboards, KPI frameworks, and management cadence.
- Take ownership of the monthly close and frame financial performance in a way leadership can act on.
- Stabilize critical finance and operating gaps when teams are lean, spanning treasury, procurement, operations, and investor communications.
Performance Tracking
How disciplined finance leadership compounds over time
An illustrative view of how stronger forecasting, tighter cost control, and KPI discipline can improve operating performance and company value over time.
Selected Results From
Prior Leadership Roles
Measurable outcomes from prior executive leadership roles across global biopharmaceutical organizations.
~600%
Market Cap Growth
MannKind Corporation
Vice President of Finance & Treasurer, 2017–2025
Partnered with the executive team to deliver 600% market capitalization growth through disciplined FP&A and capital strategy over seven years.
Mandate
Board reporting, decision support, and capital allocation discipline
20%+
Reporting Cycle Reduction
MannKind Corporation
Vice President of Finance & Treasurer
Automated reporting workflows through Power BI, reducing cycle times by 20%+ and accelerating executive decision-making.
Mandate
KPI dashboards and executive operating cadence
150+
Global FP&A Community
Bristol Myers Squibb
FP&A COE Lead, 2015–2016
Built and led a 150+ person global FP&A community, raising process standards and leadership capability across Bristol Myers Squibb.
Mandate
FP&A transformation and leadership capability building
$17B
Planning Scope
Bristol Myers Squibb
Director, Corporate FP&A, 2011–2015
Led the enterprise Long-Range Plan and served as Global Finance Lead for the Virology, Neuroscience, and Immunoscience franchises.
Mandate
Enterprise long-range planning, board-level investment decision support, and strategic prioritization across the business
Ready to strengthen finance leadership before your next inflection point?
Clearer board materials. Tighter cash visibility. Sharper KPI cadence. Faster decision support when timing matters.
First 30-minute consultation at no cost.